|Bid||4.26 x 900|
|Ask||4.28 x 900|
|Day's Range||4.08 - 4.68|
|52 Week Range||3.61 - 27.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
Today, Zosano Pharma is trading at a stock price of $4.38, which represents ~5.92% growth from its closing price of $4.14 yesterday. $4.14 represented ~15% growth from the stock’s 52-week low of $3.61 on February 13. Zosano Pharma hit a 52-week high of $27.8 on July 18, 2017.
Peer-reviewed article published in Journal of Pharmaceutical Science evaluates skin tolerability and bioavailability of ADAM’ s intracutaneous zolmitriptan delivery. FREMONT, Calif., July 17, 2018-- Zosano ...
Stock Research Monitor: VYGR, VTVT, and ZSAN LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration . WallStEquities.com recalls ...
Yes, you're reading this right. BTIG analyst Robert Hazlett is expecting Zosano Pharma (NASDAQ:ZSAN) shares to reach $19.00 in the next 12 months, which implies an upside of 400% from current levels. In a very upbeat and promising report, Hazlett explains why he is initiating coverage on ZSAN with a Buy rating: "We believe M&A potential exists with Zosano [...] Since Zosano is effectively a one product company with a modest infrastructure, there is a reasonable chance that a larger industry suitor could emerge and take over the company’s operations. The analyst continued, "We assess the total value of M207 at $16.21 per ZSAN share, assuming Zosano continues to operate independently.
Zosano Pharma, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies that deliver rapid systemic absorption using a novel and proprietary technology called Adhesive Dermally-Applied Microarray (“ADAM™”) with the potential to transform patient lives and advance patient care, announced additional analyses from the Phase 2/3 clinical study on pain relief by time and recurrence of migraine in subjects with pain relief at two hours will be presented at the American Headache Society Meeting. A poster and oral presentation on receptor and binding kinetics will also be presented during the 60th Annual Scientific Meeting to be held on June 28 – July 1, 2018 in San Francisco, CA.
Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announces the recent publication of a peer-reviewed paper regarding ADAM technology for the delivery of zolmitriptan in the Journal of Pharmaceutics. “Our in vitro study presents guidance on use of the appropriate skin model to assess intracutaneous delivery of compounds using the ADAM platform. This particular study, assessing the intracutaneous delivery of zolmitriptan, is the first of its kind and we are excited to present the results,” said Hayley Lewis, senior vice president, operations at Zosano Pharma.
NEW YORK, May 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ANSYS, ...
Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.
Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that Headache, the Journal of Head and Face Pain, has published the post-hoc analysis on the use of most bothersome symptom (MBS) as a co-primary endpoint from the Company’s ZOTRIP pivotal study. Headache published the paper titled “Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial”. The paper analyzes the positive MBS results from Zosano’s ZOTRIP pivotal study, a multi-center, double-blind, placebo-controlled trial demonstrating the efficacy and safety of M207, Zosano’s novel proprietary formulation of zolmitriptan using its ADAM technology. The ZOTRIP pivotal study, evaluating ADAM zolmitriptan for the acute treatment of migraine, was one of the first large studies to incorporate MBS freedom and pain freedom as co-primary endpoints, per recently issued guidance by the US Food and Drug Administration. MBS freedom at two hours was observed in 68% of M207 3.8 mg subjects as compared to 43% of placebo subjects (P
Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that Steven A. Elms, Managing Partner at Aisling Capital, has been appointed to the Company’s Board of Directors. "On behalf of our entire Board, I am pleased to welcome Steven as a member of our Board of Directors," commented John Walker, Chief Executive Officer and Chairman of the Board.
Completion of follow on offering netting $45.7 million Issuance of new US patent Long-term safety study now has 250 subjects enrolled. FREMONT, Calif., May 15, 2018-- Zosano Pharma Corporation a clinical-stage ...
Zosano Pharma Corp. (ZSAN) (“Zosano” or the “Company”), a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that the 250th subject has enrolled and received M207 in the M207-ADAM study (the “Study”), a long-term safety study for the acute treatment of migraines.
Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that it will host a conference call and webcast to be held on Tuesday, May 15, 2018 at 4:30PM ET. The Company will announce its financial results for this period in a press release to be issued prior to the call. To access the live webcast, please visit the Investor Relations page of the Zosano Pharma website at http://ir.zosanopharma.com/events.cfm.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tesla Inc (NASDAQ: TSLA ) stock rebounded modestly ...
Stock Monitor: Albireo Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Zosano Pharma Corp. (NASDAQ: ZSAN ) ("Zosano"). ...
Zosano Pharma Corporation (NASDAQ:ZSAN), a medical equipment company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. As aRead More...
IN THE NEWS Zosano Pharma Corp (NASDAQ: ZSAN ) stock rocketed higher by more than 50 percent Thursday and is now up 295 percent in the past week after coming alive following a new patent last Friday: Link ...